The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy

Ovarian cancer (OC) has a high impact on morbidity and mortality in the female population. Survival is modest after platinum progression. Therefore, the search for new therapeutic strategies is of utmost importance. BRCA mutations and HR-deficiency occur in around 50% of OC, leading to increased res...

Descripción completa

Detalles Bibliográficos
Autores principales: Maiorano, Brigida Anna, Lorusso, Domenica, Maiorano, Mauro Francesco Pio, Ciardiello, Davide, Parrella, Paola, Petracca, Antonio, Cormio, Gennaro, Maiello, Evaristo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8998760/
https://www.ncbi.nlm.nih.gov/pubmed/35409229
http://dx.doi.org/10.3390/ijms23073871

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8998760/
https://www.ncbi.nlm.nih.gov/pubmed/35409229
http://dx.doi.org/10.3390/ijms23073871

Ejemplares similares